Compare Genuine Parts Company (GPC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs TG Therapeutics Inc — how do they compare? Genuine Parts Company trades at $127.02 (market cap $17.67B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Genuine Parts Company is far larger — about 2.2× TG Therapeutics Inc's market cap, and Genuine Parts Company pays a 3.32% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and TG Therapeutics Inc for 16 Days on average.
| GPC | TGTX | |
|---|---|---|
Market Cap | $17.67B | $8.16B |
Volume | 1,079,458 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $59.06 |
52-Week Low | $92.47 | $26.94 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $23.76B | $8.37B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 2.2% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss, while profitability metrics like net income margin remain thin at 0.13%. The company's planned separation into automotive and industrial units by Q1 2027 is a key catalyst, supported by steady revenue growth to $24.3 billion in 2025.
The outlook is cautiously optimistic, with upside potential from the corporate split and dividend stability, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though execution risks and economic sensitivity warrant monitoring.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
